Mustang Bio shares are trading higher after the company announced safety and efficacy data from the complete Waldenstrom Macroglobulinemia cohort of its Phase 1/2 clinical trial of MB-106, showing an overall response rate of 90% with one patient remaining in complete remission at 31 months.
Portfolio Pulse from Benzinga Newsdesk
Mustang Bio shares are trading higher after the company announced positive safety and efficacy data from its Phase 1/2 clinical trial of MB-106 for Waldenstrom Macroglobulinemia, showing a 90% overall response rate and one patient in complete remission for 31 months.
June 17, 2024 | 12:35 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Mustang Bio shares are trading higher following the announcement of positive safety and efficacy data from its Phase 1/2 clinical trial of MB-106, with a 90% overall response rate and one patient in complete remission for 31 months.
The positive clinical trial results for MB-106 are likely to boost investor confidence in Mustang Bio's pipeline, leading to a short-term increase in the stock price. The high response rate and long-term remission data are particularly encouraging.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100